The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Open accessAbstract
Toll-like receptors (TLRs) are prototypic pattern recognition receptors (PRRs) best known for their ability to activate the innate immune system in response to conserved microbial components such as lipopolysaccharide and double-stranded RNA. Accumulating evidence indicates that the function of TLRs is not restricted to the elicitation of innate immune responses against invading pathogens. TLRs have indeed been shown to participate in tissue repair and injury-induced regeneration as well as in adaptive immune responses against cancer. In particular, TLR4 signaling appears to be required for the efficient processing and cross-presentation of cell-associated tumor antigens by dendritic cells, which de facto underlie optimal therapeutic responses to some anticancer drugs. Thus, TLRs constitute prominent therapeutic targets for the activation/intensification of anticancer immune responses. In line with this notion, long-used preparations such as the Coley toxin (a mixture of killed Streptococcus pyogenes and Serratia marcescens bacteria) and the bacillus Calmette-Guérin (BCG, an attenuated strain of Mycobacterium bovis originally developed as a vaccine against tuberculosis), both of which have been associated with consistent anticancer responses, potently activate TLR2 and TLR4 signaling. Today, besides BCG, only one TLR agonist is FDA-approved for therapeutic use in cancer patients: imiquimod. In this Trial Watch, we will briefly present the role of TLRs in innate and cognate immunity and discuss the progress of clinical studies evaluating the safety and efficacy of experimental TLR agonists as immunostimulatory agents for oncological indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 2×
“The main ligand of TLR9 is bacterial/viral DNA, differing from its mammalian counterpart for the elevated frequency of unmethylated CpG dinucleotides.(178) Indeed, whereas mammalian DNA has no immunostimulatory activity, the administration of bacterial/viral DNA induces a potent Th1 immune response in vivo, which is e…”
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
Self-citationCpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“In this context, TLR4 appears to bind both HSP70 and HMGB1, thus enhancing the processing of tumor antigens by DCs and their cross-presentation to T cells.(37,47,51) In line with these observations, loss-of function polymorphisms of TLR4 have been shown to negatively influence the response of breast cancer patients to…”
Self-citationSterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., & Cerami, A. (1987) · Nature · doi:10.1038/330662a0 · Cited by 2,448 · cited 1×
“Early clinical trials sought to determine the safety of LPS, with particular attention to the fact that circulating LPS might cause the sequential release into the circulation of large amounts of pro-inflammatory cytokines, a potentially lethal process that is known as endotoxic shock.(72,73) These studies determined…”
Research works printed but not linked: 242
- 10.1016/0092-8674(85)90275-2 · DOI · Paper page
- 10.1016/0092-8674(88)90516-8 · DOI · Paper page
- 10.1016/S0092-8674(00)80172-5 · DOI · Paper page
- 10.1038/351355b0 · DOI · Paper page
- 10.1093/dnares/1.1.27 · DOI · Paper page
- 10.1006/geno.1996.0150 · DOI
- 10.1038/41131 · DOI · Paper page
- 10.1038/26239 · DOI · Paper page
- 10.1126/science.282.5396.2085 · DOI · Paper page
- 10.1126/science.270.5243.1804 · DOI · Paper page
- 10.1016/S1097-2765(00)80265-8 · DOI · Paper page
- 10.1073/pnas.0502272102 · DOI · Paper page
- 10.1126/science.1102218 · DOI · Paper page
- 10.1038/nrd3203 · DOI · Paper page
- 10.1016/S0167-4781(00)00289-X · DOI · Paper page
- 10.4049/jimmunol.0901888 · DOI · Paper page
- 10.4049/jimmunol.174.5.2942 · DOI · Paper page
- 10.1371/journal.pone.0012713 · DOI
- 10.1186/1742-2094-5-53 · DOI
- 10.1126/science.1094351 · DOI · Paper page
- 10.1126/science.1109893 · DOI · Paper page
- 10.1074/jbc.M110.171025 · DOI
- 10.1074/jbc.M110.159590 · DOI · Paper page
- 10.1038/35092578 · DOI · Paper page
- 10.1016/S1097-2765(00)80136-7 · DOI · Paper page
- 10.1038/nature01889 · DOI · Paper page
- 10.1126/science.1087262 · DOI · Paper page
- 10.1038/nature03464 · DOI · Paper page
- 10.1038/ni986 · DOI · Paper page
- 10.4049/jimmunol.1003093 · DOI
- 10.1002/eji.201040547 · DOI
- 10.1074/jbc.M200497200 · DOI · Paper page
- 10.4049/jimmunol.164.1.13 · DOI · Paper page
- 10.1097/PPO.0b013e3182325d4d · DOI
- 10.4049/jimmunol.174.8.5016 · DOI · Paper page
- 10.4049/jimmunol.168.12.5989 · DOI · Paper page
- 10.1038/nrc2541 · DOI · Paper page
- 10.4161/cc.8.23.10191 · DOI
- 10.1126/science.1208347 · DOI · Paper page
- 10.4161/cc.8.22.10026 · DOI · Paper page
- 10.4161/auto.19009 · DOI
- 10.4049/jimmunol.182.3.1449 · DOI · Paper page
- 10.4161/onci.1.2.19026 · DOI
- 10.1038/nrd3626 · DOI · Paper page
- 10.1111/j.1600-065X.2007.00573.x · DOI · Paper page
- 10.1189/jlb.0103026 · DOI · Paper page
- 10.1128/IAI.71.8.4238-4249.2003 · DOI
- 10.1158/0008-5472.CAN-03-1518 · DOI
- 10.1038/ni758 · DOI · Paper page
- 10.1126/science.1177319 · DOI · Paper page
- 10.1038/nrd1880 · DOI
- 10.1126/science.1138963 · DOI · Paper page
- 10.1056/NEJMp078053 · DOI · Paper page
- 10.4049/jimmunol.175.7.4641 · DOI · Paper page
- 10.1189/jlb.0807586 · DOI · Paper page
- 10.4049/jimmunol.165.7.3541 · DOI · Paper page
- 10.4049/jimmunol.165.5.2683 · DOI
- 10.1016/j.mimet.2007.11.016 · DOI
- 10.1111/j.1349-7006.2008.00832.x · DOI
- 10.1038/1911111a0 · doi:10.1038/1911111a0
- Mizuno D, 1968, Cancer Res, 28, 1531
- 10.1002/ijc.2910250317 · doi:10.1002/ijc.2910250317
- 10.1227/01.NEU.0000249280.61761.2E · DOI
- 10.1158/1078-0432.CCR-10-3262 · DOI
- 10.1038/348550a0 · DOI · Paper page
- Engelhardt R, 1991, Cancer Res, 51, 2524
- 10.1159/000163659 · DOI
- 10.1016/0959-8049(96)00186-4 · DOI
- 10.1111/j.1348-0421.1967.tb00350.x · DOI · Paper page
- 10.1097/01.cji.0000192106.32206.30 · DOI
- Hironaka K, 2006, Anticancer Res, 26, 3701
- 10.1016/0959-8049(93)90291-M · DOI
- 10.1016/S0002-9610(05)80068-6 · DOI
- 10.1023/A:1026428918301 · DOI
- 10.1046/j.1432-1327.2000.01370.x · doi:10.1046/j.1432-1327.2000.01370.x
- 10.4049/jimmunol.180.11.7574 · DOI
- 10.1016/j.intimp.2005.02.013 · doi:10.1016/j.intimp.2005.02.013
- 10.1016/j.ijrobp.2006.07.1381 · DOI
- 10.1371/journal.pone.0018833 · DOI
- 10.4049/jimmunol.172.6.3712 · DOI · Paper page
- 10.1517/13543784.16.7.935 · DOI
- 10.1126/science.1115253 · DOI · Paper page
- 10.1126/science.1155406 · DOI · Paper page
- 10.4049/jimmunol.176.8.4894 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-1890 · DOI
- 10.1158/0008-5472.CAN-10-3490 · DOI
- 10.1073/pnas.64.1.67 · doi:10.1073/pnas.64.1.67
- 10.1016/j.vaccine.2008.10.024 · DOI
- 10.1089/jir.1986.6.373 · doi:10.1089/jir.1986.6.373
- 10.1097/00000421-198708000-00003 · doi:10.1097/00000421-198708000-00003
- Carter WA, 1985, J Biol Response Mod, 4, 613
- Carter WA, 1985, J Biol Response Mod, 4, 495
- Hubbell HR, 1987, J Biol Response Mod, 6, 525
- 10.2176/nmc.38.469 · doi:10.2176/nmc.38.469
- 10.1073/pnas.0605978104 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-1162 · DOI
- Harrison SD, 1990, J Biol Response Mod, 9, 395
- 10.1073/pnas.1113099109 · DOI · Paper page
- 10.4161/cbt.10.12.13450 · DOI
- 10.1158/1078-0432.CCR-10-1140 · DOI
- Brodsky I, 1985, J Biol Response Mod, 4, 669
- 10.1093/infdis/132.4.434 · DOI · Paper page
- 10.1126/science.408923 · doi:10.1126/science.408923
- 10.1093/infdis/137.1.78 · doi:10.1093/infdis/137.1.78
- 10.1093/infdis/137.4.428 · doi:10.1093/infdis/137.4.428
- 10.1111/j.1348-0421.1982.tb00185.x · doi:10.1111/j.1348-0421.1982.tb00185.x
- Levine AS, 1978, Cancer Treat Rep, 62, 1907
- Lampkin BC, 1985, Cancer Res, 45, 5904
- 10.1023/A:1006458232384 · doi:10.1023/a:1006458232384
- Durie BG, 1985, J Biol Response Mod, 4, 518
- 10.1089/jir.1982.2.1 · DOI
- 10.1111/j.1749-6632.2009.04932.x · DOI
- 10.1007/s11060-008-9693-3 · DOI
- 10.1007/s11060-008-9705-3 · DOI
- 10.1093/neuonc/noq071 · doi:10.1093/neuonc/noq071
- 10.1158/1078-0432.CCR-09-3106 · DOI · Paper page
- Hawkins MJ, 1985, J Biol Response Mod, 4, 664
- 10.1016/0090-8258(86)90313-6 · doi:10.1016/0090-8258(86)90313-6
- Droller MJ, 1987, J Urol, 137, 202, 10.1016/S0022-5347(17)43953-X · doi:10.1016/s0022-5347(17)43953-x
- Krown SE, 1985, J Biol Response Mod, 4, 640
- Stevenson HC, 1985, J Biol Response Mod, 4, 650
- Ewel CH, 1992, Cancer Res, 52, 3005
- 10.1158/1078-0432.CCR-11-0891 · DOI
- 10.1586/erv.11.20 · DOI
- Panter G, 2009, Curr Opin Mol Ther, 11, 133
- 10.1126/science.157.3790.819 · doi:10.1126/science.157.3790.819
- 10.1093/intimm/dxm112 · DOI
- 10.4049/jimmunol.176.3.1363 · doi:10.4049/jimmunol.176.3.1363
- 10.1038/nature06765 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-0274 · DOI · Paper page
- 10.1007/s00262-008-0459-8 · DOI
- 10.1158/0008-5472.CAN-05-0784 · DOI · Paper page
- 10.1016/S0140-6736(80)90057-4 · DOI
- 10.1023/A:1006498121628 · DOI
- 10.1016/0192-0561(90)90084-Z · doi:10.1016/0192-0561(90)90084-z
- 10.1093/annonc/mdm536 · DOI
- Lacour J, 1992, Eur J Surg Oncol, 18, 599
- Ducret JP, 1985, J Biol Response Mod, 4, 129
- 10.1089/jir.1996.16.631 · doi:10.1089/jir.1996.16.631
- 10.1038/nri3027 · DOI
- 10.1172/JCI36551 · DOI · Paper page
- 10.1126/science.1093620 · DOI · Paper page
- 10.1016/j.ymthe.2005.11.002 · DOI · Paper page
- 10.1158/0008-5472.CAN-10-3903 · DOI
- 10.1006/cimm.1999.1555 · DOI
- 10.1006/cimm.1998.1406 · DOI · Paper page
- 10.4049/jimmunol.175.3.1551 · DOI · Paper page
- 10.1006/cimm.2000.1673 · DOI
- 10.1006/cimm.2000.1689 · DOI
- 10.1016/j.vaccine.2009.07.062 · DOI
- 10.1086/513276 · DOI
- 10.1016/j.jhep.2007.02.025 · DOI · Paper page
- 10.1111/j.1365-2133.2008.08615.x · doi:10.1111/j.1365-2133.2008.08615.x
- 10.1186/1471-2172-8-26 · DOI
- 10.1089/jir.2007.0097 · DOI
- 10.4161/cbt.10.2.12163 · DOI
- 10.1158/1078-0432.CCR-07-1443 · DOI · Paper page
- 10.1177/0091270007303766 · DOI
- 10.1158/1078-0432.CCR-07-1938 · DOI
- 10.1007/s00262-010-0914-1 · DOI
- 10.1158/1078-0432.CCR-11-1625 · DOI · Paper page
- 10.1038/nrd2059 · DOI · Paper page
- 10.1038/sj.onc.1210911 · DOI · Paper page
- 10.1038/ni1280 · DOI · Paper page
- 10.1182/blood-2009-03-213363 · DOI
- Carpentier AF, 1999, Cancer Res, 59, 5429
- Carpentier AF, 2000, Clin Cancer Res, 6, 2469
- 10.1007/s00262-008-0586-2 · DOI
- 10.1002/ijc.21131 · DOI
- Paul S, 2003, Curr Opin Mol Ther, 5, 553
- 10.1007/s10875-004-6244-3 · DOI · Paper page
- 10.1016/j.vaccine.2004.01.058 · DOI · Paper page
- 10.1086/533467 · DOI
- 10.1158/1078-0432.CCR-07-0050 · DOI
- 10.1097/00002371-200411000-00006 · DOI · Paper page
- 10.1172/JCI23373 · doi:10.1172/jci23373 · Paper page
- 10.1158/1078-0432.CCR-07-4711 · DOI
- 10.3109/10428194.2011.608451 · DOI
- 10.1097/01.cji.0000211304.60126.8f · DOI
- 10.1158/1078-0432.CCR-07-0815 · DOI
- 10.1200/JCO.2010.28.9793 · DOI · Paper page
- 10.1016/j.jaad.2009.12.052 · DOI
- 10.1097/CJI.0b013e318174a4df · DOI
- 10.1200/JCO.2006.07.9129 · DOI · Paper page
- 10.1002/cncr.24473 · DOI
- 10.1097/CJI.0b013e31825481fe · DOI
- 10.1111/j.1349-7006.2010.01732.x · doi:10.1111/j.1349-7006.2010.01732.x
- 10.1200/JCO.2007.12.5807 · DOI · Paper page
- 10.1111/j.1349-7006.2009.01361.x · DOI
- 10.1200/JCO.2010.32.8971 · DOI
- 10.3816/CGC.2009.n.025 · DOI
- 10.1158/1078-0432.CCR-10-1811 · DOI
- 10.1517/13543784.7.9.1475 · DOI
- 10.1093/annonc/mdr030 · DOI
- 10.1215/S1522851705000475 · DOI · Paper page
- 10.1093/neuonc/nop047 · DOI · Paper page
- 10.1042/BST0351461 · DOI
- 10.1073/pnas.0501729102 · DOI
- Wang D, 2004, Int J Oncol, 24, 901
- 10.1158/1078-0432.CCR-09-1599 · DOI
200 of 242 shown
Cited by
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Self-citationClassification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Self-citation(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Self-citationTrial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Self-citation
Metadata
- Authors
- Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2012-08
- Volume
- 1
- Issue
- 5
- Pages
- 699-739
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W1977957999
- Cited by
- 195
- References
- 16
- FWCI
- 12.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. https://app.cochat.ai/papers/10.4161/onci.20696
- The paper
- Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. OncoImmunology. https://doi.org/10.4161/onci.20696
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.